Report Code : CVMI2603252601377 | Published Date : March 30, 2025

1 | Market Overview

The global intravenous immunoglobulin (IVIG) market is growing rapidly due to the increasing prevalence of primary and secondary immunodeficiency disorders, autoimmune diseases, and neurological conditions. IVIG is a plasma-derived therapy used to enhance the immune response or suppress abnormal immune activity. It is administered intravenously to treat a wide range of disorders, such as chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, primary immunodeficiencies (PIDs), and idiopathic thrombocytopenic purpura (ITP).

Technological advancements in plasma fractionation, enhanced supply chain logistics, and increasing awareness among healthcare professionals are driving IVIG adoption. Both governments and private organizations are also expanding reimbursement and plasma collection infrastructure.

 

2 | Market Size and Forecast

Year

Market Value (USD Billion)

Notes

2019

9.3

Historical baseline

2024

16.4

Five-year CAGR 11.4%

2031

34.2

Seven-year CAGR 11.2%

The market is expected to more than double by 2031, driven by therapeutic expansion and a growing base of immunocompromised patients.

 

3 | Key Market Drivers

  • Rising Prevalence of Immunodeficiency and Autoimmune Diseases: Increasing diagnoses of PIDs and CIDP.
  • Expanding Use in Neurology and Hematology: IVIG serves as a cornerstone in numerous immune-mediated neurological therapies.
  • Plasma Collection Enhancements: Enhancing donor recruitment and plasma fractionation efficiency.
  • Favorable Reimbursement Policies: Strong support from payers in North America and parts of Europe.

 

4 | Market Challenges

  • Supply Chain Constraints: Scarcity of plasma and extended manufacturing cycles.
  • High treatment cost: IVIG is among the most expensive biologics.
  • Stringent Regulatory Compliance: Quality and safety standards for plasma-derived therapies are intricate.

 

5 | Competitive Landscape

The IVIG market is consolidated, with global leaders in plasma therapeutics dominating production, branding, and distribution.

Market Share Estimates (2024):

Company

Estimated Market Share

Key Products

Takeda Pharmaceuticals

28%

Gammagard®, GAMUNEX®-C

Grifols

23%

Flebogamma®, Gamunex®, XEMBIFY® (SC)

CSL Behring

21%

Privigen®, Hizentra® (SC)

Octapharma

14%

Octagam®, Panzyga®

Others (Kedrion, Biotest, China Biologic)

14%

Regional brands and niche formulations

 

6 | Market Segmentation
By Indication:

  • Primary Immunodeficiency
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Guillain-Barré Syndrome
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Others (Kawasaki Disease, Myasthenia Gravis)

 

By End User:

  • Hospitals
  • Specialty Clinics
  • Home Infusion Centers

 

By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

 

7 | Strategic Outlook

Market growth will be sustained by next-generation IVIG formulations, subcutaneous alternatives, and strategic investments in expanding the donor network. Companies focusing on product differentiation, digital infusion tracking, and global access programs will drive long-term gains






Reasons To Buy

Image



Scope

Image

Key Players

  • CSL Behring
  • Grifols
  • Takeda
  • Octapharma
  • Kedrion
  • Biotest
  • ADMA Biologics
  • China Biologic Products

Intravenous Immunoglobulin Market Report



  1. 1. Intravenous Immunoglobulin Market Research Report
    1. 1.1 Study Objectives
    2. 1.2 Intravenous Immunoglobulin Market - Overview
    3. 1.3 Reason to Read This Report
    4. 1.4 Methodology and Forecast Analysis
  2. 2. Intravenous Immunoglobulin Market Research Report - Preface
    1. 2.1 Intravenous Immunoglobulin Market Research Report – Detailed Scope and Definitions
      1. 2.1.1 By Indication:
      2. 2.1.2 By End User:
      3. 2.1.3 By Region
  3. 3. Intravenous Immunoglobulin Market Dynamics
    1. 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers
    2. 3.2. Restraints – By Indication:, By End User:, By Country
    3. 3.3. Opportunities – By Indication:, By End User:, By Country
    4. 3.4. Trends – By Indication:, By End User:, By Country
    5. 3.5. PEST Analysis
    6. 3.6. Porters Five Rule Analysis
    7. 3.7. Company’s Share Analysis (CSA) by Region or By Country
    8. 3.8. Intravenous Immunoglobulin Market Research Report – DROTs Impact Analysis
    1. 4. Intravenous Immunoglobulin Market Research Report, Historic Data 2019 - 2023 and Forecast Analysis Data 2024 - 2031
    2. 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 4.2. Annual Market Trend Assessment – Year-on-Year (YoY) Growth Analysis (%)
    4. 4.3. Incremental Market Value/Volume Opportunity between 2019 - 2023 and 2024 - 2031
    5. 4.4. Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
  1. 5. Intravenous Immunoglobulin Market, By Indication:, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 5.1 Primary Immunodeficiency
    2. 5.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 5.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 5.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 5.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 5.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    7. 5.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 5.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 5.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 5.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    11. 5.3 Guillain-Barré Syndrome
    12. 5.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    13. 5.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    14. 5.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    15. 5.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    16. 5.4 Idiopathic Thrombocytopenic Purpura (ITP)
    17. 5.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    18. 5.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    19. 5.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    20. 5.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    21. 5.5 Others (Kawasaki Disease, Myasthenia Gravis)
    22. 5.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    23. 5.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    24. 5.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    25. 5.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. Intravenous Immunoglobulin Market, By End User:, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 6.1 Hospitals
    2. 6.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 6.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 6.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 6.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 6.2 Specialty Clinics
    7. 6.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 6.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 6.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 6.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    11. 6.3 Home Infusion Centers
    12. 6.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    13. 6.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    14. 6.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    15. 6.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
  1. 7. Intravenous Immunoglobulin Market Forecast, By Region, 2019 - 2023 and 2024 - 2031 (Market Value, In USD Mn)
    1. 7.1 North America
      1. 7.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.2 Europe
      1. 7.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.3 Asia-Pacific
      1. 7.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.4 Latin America
      1. 7.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.5 Middle East and Africa
      1. 7.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.6 Intravenous Immunoglobulin Market - Opportunity Analysis Index, By Indication:, By End User:, and Region, 2024 - 2031
  1. 8. North America Intravenous Immunoglobulin Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 8.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.1.1 Primary Immunodeficiency
      2. 8.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. 8.1.3 Guillain-Barré Syndrome
      4. 8.1.4 Idiopathic Thrombocytopenic Purpura (ITP)
      5. 8.1.5 Others (Kawasaki Disease, Myasthenia Gravis)
      8.2 By End User: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.2.1 Hospitals
      2. 8.2.2 Specialty Clinics
      3. 8.2.3 Home Infusion Centers
      8.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.3.1 United States
      2. 8.3.2 Canada
    2. 8.4 North America Intravenous Immunoglobulin Market – Opportunity Analysis Index, By Indication:, By End User:, and Country, 2024 - 2031
    3. 8.5 Regional Trends Analysis
    4. 8.6 North America Intravenous Immunoglobulin Market Research Report - Company Profiles
      1. 8.6.1 Company 1 (United States)
      2. 8.6.2 Company 2 (Canada)
      3. 8.6.3 Company 3 (Canada)
    9. Europe Intravenous Immunoglobulin Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 9.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.1.1 Primary Immunodeficiency
      2. 9.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. 9.1.3 Guillain-Barré Syndrome
      4. 9.1.4 Idiopathic Thrombocytopenic Purpura (ITP)
      5. 9.1.5 Others (Kawasaki Disease, Myasthenia Gravis)
      9.2 By End User: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.2.1 Hospitals
      2. 9.2.2 Specialty Clinics
      3. 9.2.3 Home Infusion Centers
      9.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.3.1 Germany
      2. 9.3.2 United Kingdom
      3. 9.3.3 France
      4. 9.3.4 Spain
      5. 9.3.5 Italy
      6. 9.3.6 Russia
    2. 9.4 Europe Intravenous Immunoglobulin Market – Opportunity Analysis Index, By Indication:, By End User:, and Country, 2024 - 2031
    3. 9.5 Regional Trends Analysis
    4. 9.6 Europe Intravenous Immunoglobulin Market Research Report - Company Profiles
      1. 9.6.1 Company 1 (Germany)
      2. 9.6.2 Company 2 (United Kingdom)
      3. 9.6.3 Company 3 (United Kingdom)
    10. Asia-Pacific Intravenous Immunoglobulin Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 10.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.1.1 Primary Immunodeficiency
      2. 10.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. 10.1.3 Guillain-Barré Syndrome
      4. 10.1.4 Idiopathic Thrombocytopenic Purpura (ITP)
      5. 10.1.5 Others (Kawasaki Disease, Myasthenia Gravis)
      10.2 By End User: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.2.1 Hospitals
      2. 10.2.2 Specialty Clinics
      3. 10.2.3 Home Infusion Centers
      10.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.3.1 China
      2. 10.3.2 Japan
      3. 10.3.3 India
      4. 10.3.4 South Korea
      5. 10.3.5 Australia & New Zealand
      6. 10.3.6 ASEAN
    2. 10.4 Asia-Pacific Intravenous Immunoglobulin Market – Opportunity Analysis Index, By Indication:, By End User:, and Country, 2024 - 2031
    3. 10.5 Regional Trends Analysis
    4. 10.6 Asia-Pacific Intravenous Immunoglobulin Market Research Report - Company Profiles
      1. 10.6.1 Company 1 (China)
      2. 10.6.2 Company 2 (Japan)
      3. 10.6.3 Company 3 (Japan)
    11. Latin America Intravenous Immunoglobulin Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 11.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.1.1 Primary Immunodeficiency
      2. 11.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. 11.1.3 Guillain-Barré Syndrome
      4. 11.1.4 Idiopathic Thrombocytopenic Purpura (ITP)
      5. 11.1.5 Others (Kawasaki Disease, Myasthenia Gravis)
      11.2 By End User: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.2.1 Hospitals
      2. 11.2.2 Specialty Clinics
      3. 11.2.3 Home Infusion Centers
      11.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.3.1 Brazil
      2. 11.3.2 Mexico
      3. 11.3.3 Argentina
      4. 11.3.4 Peru
      5. 11.3.5 Colombia
      6. 11.3.6 Rest of Latin America
    2. 11.4 Latin America Intravenous Immunoglobulin Market – Opportunity Analysis Index, By Indication:, By End User:, and Country, 2024 - 2031
    3. 11.5 Regional Trends Analysis
    4. 11.6 Latin America Intravenous Immunoglobulin Market Research Report - Company Profiles
      1. 11.6.1 Company 1 (Brazil)
      2. 11.6.2 Company 2 (Mexico)
      3. 11.6.3 Company 3 (Mexico)
    12. Middle East and Africa Intravenous Immunoglobulin Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 12.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.1.1 Primary Immunodeficiency
      2. 12.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. 12.1.3 Guillain-Barré Syndrome
      4. 12.1.4 Idiopathic Thrombocytopenic Purpura (ITP)
      5. 12.1.5 Others (Kawasaki Disease, Myasthenia Gravis)
      12.2 By End User: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.2.1 Hospitals
      2. 12.2.2 Specialty Clinics
      3. 12.2.3 Home Infusion Centers
      12.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.3.1 Saudi Arabia
      2. 12.3.2 UAE
      3. 12.3.3 South Africa
      4. 12.3.4 Egypt
      5. 12.3.5 Israel
      6. 12.3.6 Rest of Middle East and Africa
    2. 12.4 Middle East and Africa Intravenous Immunoglobulin Market – Opportunity Analysis Index, By Indication:, By End User:, and Country, 2024 - 2031
    3. 12.5 Regional Trends Analysis
    4. 12.6 Middle East and Africa Intravenous Immunoglobulin Market Research Report - Company Profiles
      1. 12.6.1 Company 1 (Saudi Arabia)
      2. 12.6.2 Company 2 (UAE)
      3. 12.6.3 Company 3 (UAE)
    13. Competition Landscape
    1. 13.1 Strategic Dashboard of Top Market Players
    2. 13.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
      1. 13.2.1 Biotest AG
      2. 13.2.2 Kedrion Biopharma
      3. 13.2.3 Grifols S.A.
      4. 13.2.4 Bio Products Laboratory
      5. 13.2.5 Takeda Pharmaceutical Company Limited
      6. 13.2.6 CSL Behring
      7. 13.2.7 Octapharma AG
      8. 13.2.8 Baxter International Inc.
      9. 13.2.9 LFB Group
      10. 13.2.10 China Biologic Products Holdings
      11. 13.2.11 Shanghai RAAS Blood Products
      12. 13.2.12 Hualan Biological Engineering
      13. 13.2.13 ADMA Biologics
      14. 13.2.14 Emergent BioSolutions
      15. 13.2.15 Kamada Ltd.
  1. 14. Data Collection Method and Research Approach
  2. 15. Principal Presumptions and Acronyms